Sejin Oh

Sejin Oh

Theragen Biologics Pvt. Ltd. - Gyeonggi / South Korea
Natural Sciences / Molecular Biology & Genetics
AD Scientific Index ID: 4984757
Theragen Biologics Pvt. 주정부
person_outline Sejin Oh's MOST POPULAR ARTICLES
1-) Selective cytotoxicity of the NAMPT inhibitor FK866 toward gastric cancer cells with markers of the epithelial-mesenchymal transition, due to loss of NAPRT J Lee, H Kim, JE Lee, SJ Shin, S Oh, G Kwon, H Kim, YY Choi, MA White, ... Gastroenterology 155 (3), 799-814. e13, 2018 782018
2-) Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities S Oh, J Yeom, HJ Cho, JH Kim, SJ Yoon, H Kim, JK Sa, S Ju, H Lee, ... Nature communications 11 (1), 3288, 2020 432020
3-) Pharmacogenomic Analysis Reveals CCNA2 as a Predictive Biomarker of Sensitivity to Polo-Like Kinase I Inhibitor in Gastric Cancer Y Lee, CE Lee, S Oh, H Kim, J Lee, SB Kim, HS Kim Cancers 12 (6), 1418, 2020 142020
4-) Multi-layered proteogenomic analysis unravels cancer metastasis directed by MMP-2 and focal adhesion kinase signalingY Kwon, SJ Park, BT Nguyen, MJ Kim, S Oh, H Lee, N Park, HS Kim, ...Scientific Reports 11 (1), 17130, 2021182021
5-) Emerging power of proteomics for delineation of intrinsic tumor subtypes and resistance mechanisms to anti-cancer therapiesS Oh, HS KimExpert Review of Proteomics 13 (10), 929-939, 201622016